Biotech Values

[kcalt]

IDIX

Have I read this wrong or will Novartis pay IDIX a sum nearly equal to IDIX's current mkt cap if valopicitabine makes it through approval???

If Novartis exercises its option to collaborate with us on valopicitabine, it would be required to provide development funding for this product candidate and pay us up to $525 million in license fees and other payments based upon achievement of certain regulatory milestones as updated in the amendment, as well as additional milestone payments based upon achievement of predetermined sales levels.

The additional sales milestones are icing on the cake. What's not to like even if VRTX's vx950 doesn't hit a snag in further trials?

I can't believe that the GI side effects of NM283 would be major enough to keep it off the market at 400 mg, let alone 200. With my current purchases at this price NM283's sales prospects vs vx950 are moot. The payout is there as long as it advances to market. All IMO

KC